TYP Stock Overview
A clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tryptamine Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.031 |
| 52 Week High | AU$0.036 |
| 52 Week Low | AU$0.017 |
| Beta | 0 |
| 11 Month Change | 72.22% |
| 3 Month Change | 55.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 19.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| TYP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 34.8% | -2.3% | -1.1% |
| 1Y | n/a | 61.9% | 16.1% |
Return vs Industry: Insufficient data to determine how TYP performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TYP performed against the Australian Market.
Price Volatility
| TYP volatility | |
|---|---|
| TYP Average Weekly Movement | 17.4% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: TYP's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine TYP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jason Carroll | www.tryptherapeutics.com |
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company’s program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications.
Tryptamine Therapeutics Limited Fundamentals Summary
| TYP fundamental statistics | |
|---|---|
| Market cap | AU$35.31m |
| Earnings (TTM) | -AU$7.37m |
| Revenue (TTM) | AU$1.33m |
26.6x
P/S Ratio-4.8x
P/E RatioIs TYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TYP income statement (TTM) | |
|---|---|
| Revenue | AU$1.33m |
| Cost of Revenue | AU$2.35m |
| Gross Profit | -AU$1.02m |
| Other Expenses | AU$6.35m |
| Earnings | -AU$7.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0065 |
| Gross Margin | -76.85% |
| Net Profit Margin | -555.37% |
| Debt/Equity Ratio | 3.5% |
How did TYP perform over the long term?
See historical performance and comparison